Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa
- Conditions
- Parkinson Disease
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 416
- Registration Number
- NCT00613301
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site 113, Tomiai, Japan
🇯🇵Boehringer Ingelheim Investigational Site 35, Tokyo Ota-ku, Japan
🇯🇵Boehringer Ingelheim Investigational Site 27, Chiba, Japan
Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen
- Conditions
- HypertensionMetabolic Syndrome X
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15268
- Registration Number
- NCT00613314
- Locations
- 🇵🇭
Boehringer Ingelheim Investigational Site, Vigan City. Ilocos Sur, Philippines
Open Label Study Telmisartan and Amlodipine in Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 976
- Registration Number
- NCT00614380
- Locations
- 🇨🇦
1235.7.20013 Boehringer Ingelheim Investigational Site, Corunna, Ontario, Canada
🇨🇦1235.7.20014 Boehringer Ingelheim Investigational Site, Etobicoke, Ontario, Canada
🇩🇰1235.7.45002 Boehringer Ingelheim Investigational Site, Birkerød, Denmark
Special Survey on PD Patients With Renal Dysfunction
- Conditions
- Parkinson Disease
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 107
- Registration Number
- NCT00613756
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Yufu, Japan
Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Population
- Conditions
- HIV Infections
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2009-10-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 428
- Registration Number
- NCT00614302
- Locations
- 🇮🇹
Boehringer Ingelheim Investigational Site, Torino, Italy
Survey on PD Patients With Depressive Symptoms
- Conditions
- Parkinson Disease
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1089
- Registration Number
- NCT00614575
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site 4, Yokohama, Japan
🇯🇵Boehringer Ingelheim Investigational Site 5, Sapporo, Japan
🇯🇵Boehringer Ingelheim Investigational Site 2, Yokohama, Japan
Safety and Efficacy of Mobic Inj. (Meloxicam) for the Patients With OA or RA: Observational Study
- Conditions
- OsteoarthritisArthritis, Rheumatoid
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 425
- Registration Number
- NCT00612885
- Locations
- 🇰🇷
Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 511
- Registration Number
- NCT00601523
- Locations
- 🇺🇸
248.633.01016 Boehringer Ingelheim Investigational Site, La Jolla, California, United States
🇺🇸248.633.01013 Boehringer Ingelheim Investigational Site, Oxnard, California, United States
🇦🇹248.633.43004 Boehringer Ingelheim Investigational Site, Wien, Austria
BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1058
- Registration Number
- NCT00602472
- Locations
- 🇧🇪
1218.18.32006 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪1218.18.32002 Boehringer Ingelheim Investigational Site, Huy, Belgium
🇨🇦1218.18.01003 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 701
- Registration Number
- NCT00601250
- Locations
- 🇮🇳
1218.17.91002 Boehringer Ingelheim Investigational Site, Bangalore, India
🇮🇳1218.17.91005 Boehringer Ingelheim Investigational Site, Bangalore, India
🇮🇳1218.17.91012 Boehringer Ingelheim Investigational Site, Chennai, India